JP2023532278A5 - - Google Patents
Info
- Publication number
- JP2023532278A5 JP2023532278A5 JP2022579946A JP2022579946A JP2023532278A5 JP 2023532278 A5 JP2023532278 A5 JP 2023532278A5 JP 2022579946 A JP2022579946 A JP 2022579946A JP 2022579946 A JP2022579946 A JP 2022579946A JP 2023532278 A5 JP2023532278 A5 JP 2023532278A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- sequence
- seq
- tcr
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025136019A JP2025166212A (ja) | 2020-06-25 | 2025-08-18 | 抗原特異的ｔ細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063044150P | 2020-06-25 | 2020-06-25 | |
| US63/044,150 | 2020-06-25 | ||
| PCT/US2021/039262 WO2021263211A2 (en) | 2020-06-25 | 2021-06-25 | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025136019A Division JP2025166212A (ja) | 2020-06-25 | 2025-08-18 | 抗原特異的ｔ細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023532278A JP2023532278A (ja) | 2023-07-27 |
| JP2023532278A5 true JP2023532278A5 (https=) | 2023-08-24 |
| JP7781085B2 JP7781085B2 (ja) | 2025-12-05 |
Family
ID=79281973
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579946A Active JP7781085B2 (ja) | 2020-06-25 | 2021-06-25 | 抗原特異的ｔ細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法 |
| JP2025136019A Pending JP2025166212A (ja) | 2020-06-25 | 2025-08-18 | 抗原特異的ｔ細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025136019A Pending JP2025166212A (ja) | 2020-06-25 | 2025-08-18 | 抗原特異的ｔ細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230250149A1 (https=) |
| EP (1) | EP4171587A4 (https=) |
| JP (2) | JP7781085B2 (https=) |
| CN (1) | CN116322750A (https=) |
| AU (1) | AU2021297458A1 (https=) |
| CA (1) | CA3188143A1 (https=) |
| WO (1) | WO2021263211A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4519675A4 (en) * | 2022-05-03 | 2026-04-08 | 3T Biosciences Inc | T-LYMPHOCYTE TARGET DISCOVERY |
| KR20250017213A (ko) * | 2022-05-25 | 2025-02-04 | 고쿠리츠 다이가쿠 호우징 도우카이 고쿠리츠 다이가쿠 기코우 | 폴리뉴클레오티드 |
| WO2024163292A1 (en) * | 2023-01-30 | 2024-08-08 | Board Of Regents, The University Of Texas System | T-cell receptors targeting her2 and methods of use thereof |
| EP4731758A2 (en) * | 2023-06-20 | 2026-04-29 | The Methodist Hospital | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy |
| WO2024263818A2 (en) * | 2023-06-20 | 2024-12-26 | Immunova Therapeutics Llc | Synthetic t cell receptors for enhancing memory (stem) t cells using new transmembranes and signaling domains |
| WO2025084880A1 (ko) * | 2023-10-20 | 2025-04-24 | 주식회사 이온셀 | Ct83 항원에 결합하는 car-t 세포 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2899679C (en) * | 2013-01-29 | 2023-03-21 | Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) Berlin-Buch | High avidity antigen recognizing constructs |
| CA3051222C (en) * | 2013-06-10 | 2023-01-24 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for reducing immunosupression by tumor cells |
| US10934346B2 (en) * | 2014-02-14 | 2021-03-02 | Bellicum Pharmaceuticals, Inc. | Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 |
| HK1243631A1 (zh) | 2014-10-27 | 2018-07-20 | Fred Hutchinson Cancer Research Center | 用於提高过继细胞免疫疗法效力的组合物和方法 |
| US20170335331A1 (en) * | 2014-10-31 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | Altering Gene Expression in CART Cells and Uses Thereof |
| GB201509413D0 (en) | 2015-06-01 | 2015-07-15 | Ucl Business Plc | Fusion protein |
| CA2996887A1 (en) * | 2015-09-11 | 2017-03-16 | Agenus Inc. | Engineered host cells and methods of use thereof |
| JP2019515656A (ja) * | 2016-03-15 | 2019-06-13 | キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ | キメラ抗原受容体 |
| AU2019224051A1 (en) | 2018-02-26 | 2020-09-03 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| EP3806857A4 (en) * | 2018-06-14 | 2022-03-02 | 2seventy bio, Inc. | CD79A CHIMERIC ANTIGEN RECEPTORS |
| WO2020086647A1 (en) * | 2018-10-23 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Ny-eso-1 t cell receptors and methods of use thereof |
-
2021
- 2021-06-25 CA CA3188143A patent/CA3188143A1/en active Pending
- 2021-06-25 CN CN202180056522.1A patent/CN116322750A/zh active Pending
- 2021-06-25 JP JP2022579946A patent/JP7781085B2/ja active Active
- 2021-06-25 EP EP21827918.0A patent/EP4171587A4/en active Pending
- 2021-06-25 WO PCT/US2021/039262 patent/WO2021263211A2/en not_active Ceased
- 2021-06-25 AU AU2021297458A patent/AU2021297458A1/en active Pending
- 2021-06-25 US US18/002,969 patent/US20230250149A1/en active Pending
-
2025
- 2025-08-18 JP JP2025136019A patent/JP2025166212A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023532278A5 (https=) | ||
| JP7781243B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| KR102879284B1 (ko) | 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도 | |
| US11168150B2 (en) | T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA | |
| RU2757316C2 (ru) | Новые моноклональные антитела к белку программируемой смерти 1(pd-1) | |
| KR102048477B1 (ko) | 프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도 | |
| CN108610420B (zh) | 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞 | |
| AU2016305697B2 (en) | Novel anti-PD-1 antibodies | |
| JP6588534B2 (ja) | 抗ｐｄ−１のモノクローナル抗体およびその獲得方法 | |
| NL2014935B1 (en) | T cell receptor like antibodies having fine specificity. | |
| US10618962B2 (en) | Anti-CTLA4 antibodies | |
| JP2022024054A (ja) | 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体 | |
| JP2018529327A5 (https=) | ||
| KR20190105112A (ko) | 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자 | |
| CA3066779A1 (en) | Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof | |
| CN101541834A (zh) | 癌症的预防和/或治疗剂 | |
| KR102048476B1 (ko) | 프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도 | |
| JP2022542559A5 (https=) | ||
| JP2025156298A (ja) | 抗ニューヨーク食道扁平上皮がん１（ｎｙ－ｅｓｏ－１）抗原結合タンパク質およびその使用方法 | |
| CN121248789A (zh) | 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法 | |
| JP2024526324A (ja) | Ｂｃｍａ指向性細胞免疫療法の組成物および方法 | |
| CN108948194A (zh) | 一种新的ctla-4单克隆抗体 | |
| JP2024105603A (ja) | ＣＡＲライブラリおよびｓｃＦｖの製造方法 | |
| WO2021175681A1 (en) | Novel non-immunogenic chimeric antigen receptors and uses thereof | |
| CN119278213A (zh) | 针对ctla-4的抗体及其使用方法 |